EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peripherally Restricted CB1 Receptor Inverse Agonist JD5037 Treatment Exacerbates Liver Injury in MDR2-Deficient Mice

Jenny Chen, Fengyuan Li, Jiyeon Lee, Md Manirujjaman iD, Lihua Zhang, Zhao-Hui Song, Craig McClain iD, Wenke Feng

Cells · 2024

DOI: 10.3390/cells13131101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Jenny Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB1, ATP Binding Cassette Transporter, Subfamily B, Liver Cirrhosis, ATP-Binding Cassette Sub-Family B Member 4. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIGMS NIH HHS, NIAAA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous research highlighted the involvement of the cannabinoid CB1 receptor in regulating the physiology of hepatocytes and hepatic stellate cells. The inhibition of the CB1 receptor via peripherally restricted CB1 receptor inverse agonist JD5037 has shown promise in inhibiting liver fibrosis in mice treated with CCl4. However, its efficacy in phospholipid transporter-deficiency-induced liver fibrosis remains uncertain. In this study, we investigated the effectiveness of JD5037 in Mdr2−/− mice. Mdr2 (Abcb4) is a mouse ortholog of the human MDR3 (ABCB4) gene encoding for the canalicular phospholipid transporter. Genetic disruption of the Mdr2 gene in mice causes a complete absence of phosphatidylcholine from bile, leading to liver injury and fibrosis. Mdr2−/− mice develop spontaneous fibrosis during growth. JD5037 was orally administered to the mice for four weeks starting at eight weeks of age. Liver fibrosis, bile acid levels, inflammation, and injury were assessed. Additionally, JD5037 was administered to three-week-old mice to evaluate its preventive effects on fibrosis development. Our findings corroborate previous observations regarding global CB1 receptor inverse agonists. Four weeks of JD5037 treatment in eight-week-old Mdr2−/− mice with established fibrosis led to reduced body weight gains. However, contrary to expectations, JD5037 significantly exacerbated liver injury, evidenced by elevated serum ALT and ALP levels and exacerbated liver histology. Notably, JD5037-treated Mdr2−/− mice exhibited significantly heightened serum bile acid levels. Furthermore, JD5037 treatment intensified liver fibrosis, increased fibrogenic gene expression, stimulated ductular reaction, and upregulated hepatic proinflammatory cytokines. Importantly, JD5037 failed to prevent liver fibrosis formation in three-week-old Mdr2−/− mice. In summary, our study reveals the exacerbating effect of JD5037 on liver fibrosis in genetically MDR2-deficient mice. These findings underscore the need for caution in the use of peripherally restricted CB1R inverse agonists for liver fibrosis treatment, particularly in cases of dysfunctional hepatic phospholipid transporter.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Cannabinoid, CB1ATP Binding Cassette Transporter, Subfamily BLiver CirrhosisATP-Binding Cassette Sub-Family B Member 4AnimalsMiceLiverMaleMice, KnockoutBile Acids and SaltsDrug Inverse AgonismMice, Inbred C57BL

Stichwörter der Autor:innen

Cannabinoidsliver fibrosis

Substanzen

Receptor, Cannabinoid, CB1ATP Binding Cassette Transporter, Subfamily BATP-Binding Cassette Sub-Family B Member 4Bile Acids and Salts

Autor:innen und Institutionen

  • Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
  • Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA.
  • Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.

ORCID-Profile: Md Manirujjaman, Craig McClain

Förderung

  • NIH HHS
  • NIGMS NIH HHS
  • NIAAA NIH HHS
  • National Institutes of Health

Zitieren

APA

Chen, J., Li, F., Lee, J., Manirujjaman, M., Zhang, L., Song, Z. H., McClain, C., & Feng, W. (2024). Peripherally Restricted CB1 Receptor Inverse Agonist JD5037 Treatment Exacerbates Liver Injury in MDR2-Deficient Mice. Cells. https://doi.org/10.3390/cells13131101

Vancouver

Chen J, Li F, Lee J, Manirujjaman M, Zhang L, Song ZH, et al. Peripherally Restricted CB1 Receptor Inverse Agonist JD5037 Treatment Exacerbates Liver Injury in MDR2-Deficient Mice. Cells. 2024. doi:10.3390/cells13131101

BibTeX
@article{Chen2024,
  author = {Chen, Jenny and Li, Fengyuan and Lee, Jiyeon and Manirujjaman, Md and Zhang, Lihua and Song, Zhao-Hui and McClain, Craig and Feng, Wenke},
  title = {Peripherally Restricted CB1 Receptor Inverse Agonist JD5037 Treatment Exacerbates Liver Injury in MDR2-Deficient Mice},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13131101}
}
Kostenlos starten →